Clinical trial
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic…
NCT00080340 · Telik, Industry · Completed
Key facts
| NCT number | NCT00080340 |
|---|---|
| Title | Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| Official title | Phase 3 Randomized Study of TLK286 (Telcyta) Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| Lead sponsor | Telik, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | TLK286 (Telcyta) HCl for Injection, gefitinib (Iressa) |
| Enrollment | 520 |
| Completion | May 1, 2005 |
| First posted | Mar 30, 2004 |
| Last update posted | Jan 15, 2008 |
| Countries | Argentina, Australia, Brazil, Chile, Germany, Italy, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: